High impact
74
conflict / systemic issueSentiment +25
Source
Systemic monitor
Decided
2026-09-08
Novartis’ cholesterol-drug setback weakens its position while increasing attention on Amgen’s competing Lp(a) opportunity.
Novartis’ cholesterol-drug setback weakens its position while increasing attention on Amgen’s competing Lp(a) opportunity.
We are still collecting relevant articles for AMGN. Curated events highlight the most material developments impacting this ticker right now.